News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medpace, Inc. Welcomes Piotr Krzeski, MD, PhD, MFPM, Medical Director Adding Expertise in Gastroenterology


3/28/2012 9:07:36 AM

CINCINNATI, OH--(Marketwire - March 28, 2012) -

Medpace, Inc. announced the addition of Piotr Krzeski, MD, PhD, MFPM as a Medical Director, adding expertise in gastroenterology clinical research studies. Dr. Krzeski has over 10 years of experience in drug development with global expertise in the design and medical oversight of clinical trials in the area of gastroenterology, cardiology, and rheumatology.

"An internist with a broad background in pharmaceutical research, Dr. Krzeski is recognized for contributions in pioneering work on standardization of central imaging in inflammatory bowel disease drug development," said Jonathan Isaacsohn, MD, FACC, Executive Vice President, Medpace. "His innovative experience and industry knowledge will allow Medpace to provide new methods to our sponsors engaged in bringing new drugs to market."

Dr. Krzeski completed his internal medicine training at Gastroenterology Department, Medical Postgraduate Centre, Warsaw, Poland and earned his PhD in Hepatology.

ABOUT MEDPACE
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.

Visit the Medpace website at www.medpace.com


Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES